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Lipid-coated polymeric nanoparticles for
cancer drug delivery
Sangeetha Krishnamurthy,a Rajendran Vaiyapuri,a Liangfang Zhangb and
Juliana M. Chan*a,c
Polymeric nanoparticles and liposomes have been the platform of choice for nanoparticle-based cancer
drug delivery applications over the past decade, but extensive research has revealed their limitations as
drug delivery carriers. A hybrid class of nanoparticles, aimed at combining the advantages of both poly-
meric nanoparticles and liposomes, has received attention in recent years. These core/shell type nano-
particles, frequently referred to as lipid–polymer hybrid nanoparticles (LPNs), possess several characteristics
that make them highly suitable for drug delivery. This review introduces the formulation methods used to
synthesize LPNs and discusses the strategies used to treat cancer, such as by targeting the tumor micro-
environment or vasculature. Finally, it discusses the challenges that must be overcome to realize the full
potential of LPNs in the clinic.
1. Introduction
Nanomedicine is a rapidly growing field that uses nanotechno-
logy to solve clinical problems. The National Institutes of
Health (NIH) defines nanomedicine as a molecular scale inter-
vention for the prevention, diagnosis and treatment of disease.
Currently, there is much interest in the application of nanome-
dicine for the diagnosis and treatment of cancer, which is
linked to high mortality and morbidity rates. According to the
World Health Organization, cancer is the second major cause
of death from non-communicable diseases worldwide
(8.2 million in 2012), next only to cardiovascular diseases.1
Indeed, nanomedicine has increasingly been shown to oﬀer
various advantages over traditional drug delivery methods.
Various properties make them very attractive for the treatment
of cancer: these include their small size, high surface area to
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volume ratio, ability to load multiple agents, active targeting
by conjugating targeting ligands on their surface, passive tar-
geting through the enhanced permeability and retention (EPR)
eﬀect, and an improved circulation half-life.2
Scientists have developed nanoparticles that can be
grouped into several broad classes, each with its own advan-
tages and disadvantages. These include polymeric nanoparti-
cles, liposomes, magnetic nanoparticles, micelles, gold
nanoparticles, quantum dots, dendrimers and carbon nano-
tubes.3 However, most of these nanoparticles are still at the
research stage and only a handful of them have been approved
for clinical use. The majority of clinically approved formu-
lations are liposomes and these include Doxil and Myocet.3
Clinically approved polymeric nanoparticles include Adagen,
Genexol PM, Eligard and Copaxone.3
Although preferred for their excellent biocompatibility, lipo-
somes are associated with challenges such as drug leakage
and instability during storage, leading to a short shelf-life.4
Polymeric nanoparticles show excellent loading and stability,
but on the other hand may involve complex synthetic pro-
cedures and materials, and thus require rigorous biocompat-
ibility testing before they can be brought to the clinic.5
Although some of the main hurdles in designing nanoparticle-
based drug delivery carriers have been overcome, the require-
ments of an ideal cancer drug delivery system become increas-
ingly complicated when the carrier’s interactions with the
body and the complexity of the disease are also considered.
To broadly fulfill the requirements of high biocompatibility
and drug loading capacity, it becomes desirable to combine
the advantages of the two dominant classes of drug nano-
carrier systems – liposomes and polymeric nanoparticles.
Researchers have developed hybrids of these two classes of
nanoparticles, broadly referred to as lipid–polymer hybrid
nanoparticles (LPNs), and have used them for various thera-
peutic and diagnostic applications. A typical LPN has a poly-
meric core, which is used to encapsulate the cargo to be
delivered; and a lipid shell, which provides biocompatibility.
The lipid shell may either be a monolayer or a bilayer. In some
cases, an additional layer of poly(ethylene glycol) (PEG) is
further coated onto the lipid surface to give it stealth pro-
perties in the bloodstream.6 The work by Miguel and co-
workers from 2000 is one of the earliest reported studies on
bilayer lipid-coated polymeric nanoparticle synthesis. The
bilayer LPNs were synthesized from epichlorohydrin cross-
linked polysaccharides modified with quaternary ammonium
functions and coated with a layer of lipid and cholesterol.7
Later in 2008, Zhang et al. first described a simple self-assem-
bly method to synthesize the more widely used monolayer
lipid-coated polymeric nanoparticles, which showcased mono-
layer LPNs as a robust drug delivery platform.8
Since then, there has been a large increase in the diversity
of biomaterials used for LPN synthesis and applications
reported in the literature. This review discusses the various
synthetic procedures used to prepare LPNs, the advantages
that make LPNs excellent delivery agents for cancer therapy, as
well as the applications they have been used in.
2. Preparation of LPNs
In most of the studies described here, the core of the LPN is
synthesized from clinically-approved biomaterial poly(lactide-
co-glycolide) (PLGA), owing to its biocompatibility and biode-
gradability.9 As for the lipid shell, various lipids including
phosphatidyl choline (PC),10 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine (DSPE),11,12 cholesterol,13 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC),14 myristic acid,15 stearic
acid,16 and 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC)17
have been used.
Earlier approaches to LPN synthesis used a two-step pro-
cedure, which requires that the lipid shell and the polymeric
core be prepared first, followed by a second step to fuse the
layers together. In recent years, however, a single-step
approach is increasingly preferred, giving researchers greater
ease and convenience when preparing LPNs.
2.1. Two-step approach
In the two-step approach, the lipid shell and the polymeric
core are prepared individually, before being fused together by
direct hydration,18 sonication19 or extrusion,20 to form a
bilayer LPN (Fig. 1). Electrostatic interactions between the
anionic polymeric core and the cationic lipid vesicle drive the
fusion process.21
Various mixing techniques have been used to fuse the poly-
meric cores with lipid vesicles. In one example, the solution
was heated above the lipid phase transition temperature to dis-
perse the lipid molecules, allowing for the fusion of the poly-
meric cores with preformed lipid vesicles.21 In another
example, the lipids were dried into a film and hydrated in the
presence of polymeric nanoparticles.18
Using the two-step approach, Troutier et al. synthesized
500 nm multilamellar lipoparticles by hydration using DPPC,
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DPTAP and polystyrene. Next, the nanoparticles were soni-
cated, resulting in multilamellar lipoparticles that were
∼250 nm in diameter. The nanoparticles were further sub-
jected to extrusion to give unilamellar LPNs that were 100 nm
in diameter.20 In general, large multilamellar vesicles are
formed from the hydration of dry lipid films, which require
sonication or extrusion to convert these large multilamellar
vesicles into small unilamellar vesicles that are smaller in size
and with a lower polydispersity index.
In another study, Sengupta et al. developed a combination
therapy system for the dual loading of doxorubicin and com-
bretastatin.22 The shells were formed from phosphatidyl-
choline, cholesterol, DSPE-PEG and combretastatin, while
doxorubicin-PLGA conjugates were loaded into the cores using
an emulsion/solvent evaporation method. Finally, the lipid
vesicles and polymeric core particles were fused together by
extrusion. The nanocells, as they were called, were around
180–200 nm in diameter. They exhibited two diﬀerent drug
release profiles: combretastatin was released quickly from the
shell over 12 h, while the doxorubicin-PLGA conjugates were
slowly released over 15 days as the polymer degraded and the
free drug molecules were released.
In another study, Zhao et al. reported the preparation of
folic acid-conjugated LPNs loaded with paclitaxel.18 Here, a
thin film of lipids was formed by solvent evaporation and
hydrated in a buﬀer containing paclitaxel-loaded PLGA nano-
particles. The LPNs were approximately 190 nm in diameter.
2.2. Single-step approach
In the single-step approach, the lipid, polymer and drug are
mixed together and the monolayer LPNs are prepared by self-
assembly (Fig. 2).
2.2.1. Emulsion method. In the emulsion method, water
immiscible organic solvents are used to dissolve the polymer
and drug. Bath sonication, mechanical stirring and/or heat are
used to disperse the lipid in the aqueous phase. The aqueous
and organic phases are mixed together and sonicated to dis-
perse the organic phase and allow the drug/polymer mixture
to be coated with lipids. Using a rotary evaporator or simple
overnight stirring, the organic solvent is evaporated from the
mixture and the resulting particle suspension is washed and
purified by centrifugal filtration.
One example of the emulsion method was carried out by
Palange et al., who synthesized curcumin encapsulated LPNs
for breast cancer therapy.23 They prepared an organic solution
containing curcumin, PLGA and 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), and an aqueous solution containing
DSPE-PEG in 4% ethanol solution. The oil phase was added
dropwise to the aqueous phase under ultrasonication, produ-
cing LPNs that were about 170 nm in diameter.
2.2.2. Nanoprecipitation method. In the nanoprecipitation
method, LPNs are synthesized by vortexing followed by self-
assembly. In this method, the lipid to polymer ratio, the vis-
cosity of the polymer and the volume ratio of the organic to
aqueous phase all play a vital role in the final particle dia-
meter, surface charge and polydispersity.
Using a one-step nanoprecipitation method, Zhang et al.
synthesized docetaxel loaded LPNs.8 Here, a 4% ethanol
aqueous solution containing lecithin and DSPE-PEG was
heated to 65 °C before an organic solution containing PLGA
and docetaxel was added dropwise to the aqueous solution
under vigorous stirring. The mixture was vortexed vigorously
for 3 min, and the organic solvent was removed by gentle stir-
ring for 2 h at room temperature and centrifugal filtration. The
resulting particles were about 90 nm in diameter. Similarly,
Yang et al. prepared LPNs for the systemic delivery of siRNA
using PEG-PLA/PLA and cationic lipid BHEM-Chol.24 In
another study, Huang et al. prepared LPNs for dual drug deliv-
ery by loading paclitaxel into the hydrophobic core and doxo-
rubicin into the hydrophilic shell.25
3. LPNs for cancer therapy
LPNs have several advantages over other nanoformulations
such as liposomes and polymeric nanoparticles, making them
good candidates for cancer therapy. Some of their disadvan-
tages are also discussed in section 4.
One of the main advantages of using LPNs for cancer drug
delivery is the possibility of incorporating drugs with diﬀerent
physicochemical characteristics due to the presence of distinct
lipid and polymer layers.26 The ratio of diﬀerent drugs can be
Fig. 1 Schematic representation of bilayer LPN preparation using a
two-step approach.
Fig. 2 Schematic representation of monolayer LPN preparation using a
single-step approach.
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precisely controlled, allowing researchers to co-deliver drugs to
cancer cells for a synergistic eﬀect and to overcome multi-drug
resistance.27 Hydrophobic drugs can also be co-delivered with
novel therapeutic agents such as proteins, peptides and
nucleic acids: hydrophobic small molecule drugs can be
loaded into the nanoparticle core, while hydrophilic bio-
molecules can be loaded into the lipid layer or conjugated
onto the surface.
LPNs have been shown to provide higher drug loading
capacities for hydrophobic drugs compared to polymeric nano-
particles, greater stability without drug leakage, and excellent
controlled drug release profiles.8 Their sustained release
profile is due to the slow degradation rate of polymers in the
core and also the diﬀusional barrier of the lipid shell. Stimuli-
responsive LPNs can be designed to deliver drugs specifically
to tumors using pH-sensitive and redox-sensitive LPN
systems.28
The lipid shell can be engineered as a monolayer or bilayer,
depending upon the release characteristics required and also
based on the cargo to be loaded in the lipid shell. In addition,
the lipid shell can be functionalized with targeting moieties.
By modifying LPNs with various targeting ligands, they can be
actively targeted to tumor sites in addition to an EPR eﬀect.11
The synthesis of LPNs, as discussed earlier in section 2, is
simple and straightforward, with good control over particle
size and ease of surface modification. The PEG layer on the
surface of LPNs increases its hydrophilicity, enhancing their
circulation half-life and reducing clearance by the reticulo-
endothelial system.6
In recent years, several reports using LPNs to deliver thera-
peutic agents such as cytotoxic drugs, nucleic acids and pro-
teins to tumors have been published. These studies are
classified here into seven sections, each representing a poss-
ible therapeutic option for the treatment of cancer. They are
also summarized in Table 1 for their key characteristics such
as delivery of a single agent or combination agents.
3.1. Targeting tumor cell proliferation
The delivery of cytotoxic agents to stall tumor cell proliferation
has been the main focus of researchers working on LPNs.
Many cytotoxic drugs have poor water solubility, low circula-
tion half-life, and high non-specific toxicity. So far, LPNs have
been used to deliver a variety of small molecule hydrophobic
drugs, including docetaxel,17 salidroside,13 ginsenoside,29
paclitaxel,30 camptothecin,12 doxorubicin,27,31,32 sorafenib,14
and curcumin.16
Using a single-step nanoprecipitation method, Zhang et al.
developed LPNs for the delivery of docetaxel to prostate cancer
cells.8 The nanoparticles were surface-conjugated with the A10
RNA aptamer to specifically target prostate cancer cells over-
expressing the prostate specific membrane antigen (PSMA).
The nanoparticles were shown to have high drug loading, sus-
tained drug release over 120 h, and excellent stability.
Lee et al. synthesized LPNs that were loaded with ginseno-
side Rg3, a pharmacologically active component of ginseng
shown to have anti-cancer properties by inducing apoptosis
and anti-angiogenesis.29 The nanoparticles were formulated
using a solvent evaporation technique, and contained amphi-
philic hyaluronic acid ceramide (HACE), PC and DSPE-PEG
in the shell. They showed sustained release over a period of
16 days without any observed burst release. Blank nano-
particles were eﬃciently taken up by A549 cells through
CD-44 mediated endocytosis, but had very minimal toxicity
in vitro up to nanoparticle concentrations of 500 µg mL−1. The
nanoparticles also showed a good circulation half-life profile
in a Sprague–Dawley rat model.
Apart from more conventional LPNs, researchers have also
developed stimuli-responsive LPNs to achieve greater control
over drug delivery. In one such study, 10 nm iron oxide nano-
particles and camptothecin were encapsulated in the PLGA
core, surrounded by soybean lecithin and DSPE-PEG in the
shell.33 When the nanoparticles were triggered with a radio fre-
quency (RF) magnetic field, localized heating in the nano-
particle core caused polymer degradation and drug release.
The nanoparticles showed minimal drug release under control
conditions, whereas with RF stimulation the drug release rate
increased significantly, leading to 60% cell death.
Another good example of stimuli-responsive LPNs would be
the study by Li et al., where they synthesized LPNs for the pH-
triggered delivery of mitomycin C by reverse micelle–solvent
evaporation.34 Mitomycin C and soybean phosphatidyl choline
formed a complex in the core, and PLA surrounded the core.
The micelles were further coated with a lipid layer containing
DPPE, DSPE-PEG and DSPE-PEG-folic acid conjugates. A sche-
matic illustrating the synthesis of the drug loaded LPNs is
shown in Fig. 3, as well as the mechanism of folate targeting
and drug release in the endo-lysosome. The nanoparticles
exhibited a burst release in vitro, followed by a more sustained
release over 120 h. They were taken up by A549 lung cancer
cells within 4 h as shown by fluorescence microscopy and flow
cytometry. In a xenograft mouse model, tumors treated with
the drug-loaded nanoparticles shrank more than 50%, and
folate-targeted nanoparticles accumulated better in tumors
compared to non-targeted nanoparticles.
Researchers have also designed multi-functional LPNs to
treat cancer more thoroughly. In an example of dual drug
delivery, Su and coworkers synthesized LPNs for the co-delivery
of epigenetic (2′-deoxy-5-azacytidine, DAC) and chemothera-
peutic drugs (doxorubicin).31 DAC enhances the expression of
tumor suppressor genes by inhibiting DNA methyltransferases
that cause epigenetic silencing of these protective genes.35
DAC is also hypothesized to increase the sensitivity of cancer
cells to doxorubicin. Using a nanoprecipitation method, both
DAC and doxorubicin were encapsulated in the PLGA core and
coated with a layer of lecithin and DSPE-PEG. The growth sup-
pressive eﬀects of the nanoparticles were tested on an
MB231 human breast cancer cell line and synergistic growth
inhibition was observed. In addition, HONE1 nasopharyngeal
carcinoma cells treated with DAC nanoparticles showed
better recovery in the expression of the tumor suppressor gene
DLC1 (Deleted in Liver Cancer 1) compared to treatment with
free drug.
Review Biomaterials Science
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Table 1 LPN-based therapeutics in pre-clinical development
Polymer components Lipid components Therapeutic(s) Targeting Cancer model Ref
Single agent delivery
PLGA-PEG-PLGA Cholesterol, lecithin Salidroside N/A Breast cancer and
pancreatic cancer (4T1
and PANC-1 cells)
13
Hyaluronic acid
ceramide (HACE)
Egg PC, DSPE-PEG Ginsenoside Rg3 N/A Lung cancer (A549 cells) 29
2-Hydroxyethyl
methacrylate + Choline
formate ionic liquid
Stearic acid Curcumin N/A Breast cancer (MCF-7 cells) 16
Combination agents delivery
PLGA DSPE-PEG Doxorubicin,
combretastatin A4
N/A Melanoma and Lewis lung
carcinoma (B16F10 and
Lewis lung carcinoma cells)
22
HPESO (hydrolyzed
polymer of epoxidized
soybean oil)
Tristearin–stearic
acid 30 : 70 w/w
Doxorubicin,
Elacridar (GG918)
N/A Multi-drug resistant breast
cancer (MDA435/LCC6/
MDR1 cells) breast cancer
(EMT6/WT cells)
32,71
HPESO Myristic acid Doxorubicin, mitomycin C N/A Multi-drug resistant breast
cancer (MDA-MB 435/
LCC6/MDR1 cells)
15
PLGA Soybean lecithin, DSPE-PEG 2′-Deoxy-5-azacytidine (DAC),
doxorubicin
N/A Breast cancer
(MDA-MB-231 cells)
31
PLA-PEG-PLA PC, cholesterol, DSPE-PEG TGF-β receptor-I inhibitor
(SB505124), IL-2
N/A Melanoma (B16-F10 cells) 79
Diagnostic and theranostic agents delivery
PLGA Lecithin, DSPE-PEG Iron oxide nanoparticles,
camptothecin
N/A Breast cancer (MT2 cells) 33
PLGA DPPC, DSPE-PEG Gold nanocrystals and
paclitaxel in polymer core;
sorafenib and Cy7 NIR dye
in lipid shell
N/A Colon cancer (LS174 T cells) 86
PLGA Lecithin, DSPE-PEG Doxorubicin,
Indocyanin-green NIR dye
N/A Basal cell carcinoma
(BCC cells)
54
PLGA Soybean lecithin Gold nanocrystals,
quantum dots
N/A N/A 14
Targeted LPNs
PLGA Egg PC, 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine
7 alpha-APTADD Transferrin Breast cancer (SKBR-3 cells) 10
PLGA RBC vesicles Anti-RBC IgG Targets and
neutralizes
anti-RBC IgG
N/A 88
PLGA RBC derived lipid membranes,
FITC-PEG-lipid
DiD fluorescent dye FITC, folate or
AS1411 aptamer
Breast cancer (KB cells) 89
PLA DSPE-PEG Paclitaxel (PLA-conjugated) KLWVLPK
peptide for
vascular
endothelial
targeting
N/A 62
PLGA Lecithin, DSPE-PEG Paclitaxel AS1411 anti-
nucleolin
targeted aptamer
Breast cancer (MCF-7 cells) 11
Polyamidoamine
grafted cholesterol
DOTAP : DOPE : cholesterol,
DSPE-PEG
Anti-EGFR siRNA T7 peptide
(HAIYPRH) to
target transferrin
Breast cancer (MCF-7 cells) 41
PLGA DSPE-PEG 10-Hydroxycamptothecin Cyclo(RGDyk) Breast cancer (MCF-7 and
MDA-MB-435s cells)
12
PLGA DLPC, DSPE-PEG2K,
DSPE-PEG5K
Docetaxel Folate Breast cancer (MCF-7 cells) 17
PLA Soybean PC, DSPE-PEG,
DSPE-PEG-FA
Mitomycin C Folate Lung cancer and
hepatocellular carcinoma
(A549 and H22 cells)
34
PLGA DSPE-PEG-maleimide,
lecithin
Doxorubicin Anti-EGFR
antibody
Hepatocellular carcinoma
(SMMC-7721 cells)
80
PLGA DSPE-PEG, lecithin Paclitaxel Half antibody of
anti-CEA
antibody
Pancreatic adenocarcinoma
(BxPC3 cells)
90
PLGA Lecithin, DSPE-PEG Paclitaxel, combretastatin A4 Cyclo(RGDFK) Breast cancer (MCF-7 cells) 61
PLGA PEG-OQLCS, cholesterol Doxorubicin, pEGFP Folate Breast cancer
(MDA-MB-231 cells)
36
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Researchers have also explored the use of LPNs for the co-
delivery of drugs and plasmids. Wang et al. designed LPNs
with doxorubicin in the PLGA core and GFP-encoding plas-
mids complexed in the lipid shell, which were further coated
with PEGylated amphiphilic octadecyl-quaternized lysine
modified chitosan (PEG-OQLCS) and cationic folate acid
coated amphiphilic octadecyl-quaternized lysine modified chit-
osan (FA-OQLCS).36 In comparison with uncoated PLGA nano-
particles and lipid-coated PLGA nanoparticles, lipid/folate-
coated nanoparticles showed a more sustained release profile
of doxorubicin over several days. The lipid/folate-coated nano-
particles were taken up in MDA-MB231 cells as shown by the
intracellular fluorescence of both doxorubicin and GFP. Flow
cytometry analysis showed that 46.6% of transfected cells had
taken up both the plasmids and doxorubicin. The blank nano-
particles showed negligible toxicity whereas the drug loaded
nanoparticles showed a dose-dependent toxicity that was
slightly better than free drug.
Apart from inhibiting cell proliferation, other key aspects of
cancer have also been exploited for LPN-based drug delivery.
For example, researchers have explored the use of LPNs to
deliver antisense RNA against growth-promoting oncogenes
and tumor suppressor peptides, which are discussed in the fol-
lowing sections.
3.2. Targeting cancer-promoting oncogenes
Oncogenes are overexpressed by malignant cells and have
always been a stalwart of cancer treatment strategies. One way
to specifically downregulate oncogenes is to silence them
using small interfering RNAs (siRNAs), a method that has led
to promising therapy outcomes.37 But nucleic acids are highly
charged and polyanionic, properties that do not favor cell
penetration. In addition, their large molecular weights and
rapid denaturation by nucleases in vivo necessitate the use of
delivery vectors for eﬃcient intracellular delivery.38 Research-
ers have recently become interested in delivering siRNAs in
combination with other therapeutics to silence oncogenes.
As a proof of concept for the silencing of genes involved in
tumor metabolism, researchers delivered siRNA to knock
down housekeeping genes such as glyceraldehyde 3-phosphate
dehydrogenases (GAPDH). Shi et al. developed LPNs composed
of 1,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine (DMOPC)
and GAPDH siRNA in the PLGA core, and DSPE-PEG/lecithin
mixtures in the shell.39 The nanoparticles were formed using
a modified double emulsion/solvent evaporation technique
with self-assembly. GAPDH siRNA delivered by LPNs to
HepG2 hepatocytes resulted in eﬃcient gene knockdown
in vitro and at levels comparable to commercially available
transfection reagents. In vivo eﬃcacy studies in Balb/C nude
mice showed GAPDH knockdown eﬃciencies of 42–45%.
The same group also reported the delivery of siRNA that tar-
geted prohibitin (PHB1), a gene responsible for chemoresis-
tance, cell proliferation and apoptosis.40 They synthesized
LPNs from 1,2-epoxytetradecane with PAMAM dendrimers for
the core and DSPE-PEG for the shell. PHB1 knockdown
eﬃcacy was tested in vitro in A549 cells and in vivo in an A549
xenograft mouse model. Nanoparticle treatment reduced cell
proliferation significantly in vitro and reduced mouse tumor
load by more than two-fold in vivo.
In a study that also included active targeting, Gao and co-
workers developed and tested LPNs for siRNA delivery to
cancer cells in vivo.41 The nanoparticle cores consisted of
cholesterol-grafted poly(amidoamine) (rPAA-Chol polymer),
while the shells contained DSPE-PEG modified with a peptide
(T7-HAIYPRH) that targets the transferrin receptor over-
expressed in cancer cells. The positive charge of the rPAA-Chol
polymer enabled high siRNA loading via electrostatic inter-
action. LPN synthesis and cellular uptake pathways are illus-
trated in Fig. 4. Peptide targeting was shown to improve
cellular uptake of the nanoparticles, as analyzed by fluo-
rescence microscopy and flow cytometry. In MCF-7 cells, nano-
particles loaded with anti-EGFR siRNA showed 80% gene
silencing in vitro, comparable to that when Lipofectamine
2000 is used. In an MCF-7 xenograft mouse model, the nano-
particles showed very low systemic toxicity, induced gene
knockdown, and reduced the tumor load significantly.
Using a unique technique called particle replication in non-
wetting templates (PRINT), Hasan et al. developed highly
monodisperse, uniformly sized LPNs.42 PRINT is a nano-
molding technique that oﬀers high control over size, shape
and composition of the particles synthesized. A master tem-
plate is first created using lithography, which is then loaded
with the desired material via capillary filling. Uniform particles
of desired characteristics can be peeled oﬀ from the mold
using a harvesting film.43 In this study, PLGA nanoparticles
were loaded with siRNA in the core and coated with DOTAP :
DOPE in the shell. Interestingly, the nanoparticles were syn-
thesized in a needle shape instead of the traditional spherical
shape. Previous studies had shown that needle-shaped par-
ticles were more eﬃcient at siRNA delivery than spherical-
Fig. 3 pH-responsive LPNs. (A) Mitomycin C-loaded, folate-targeted
LPNs for in vitro and in vivo targeted drug delivery. (B) An illustration of
the sequence of events leading to cytotoxicity: tumor accumulation
by the EPR eﬀect, folate-receptor mediated cancer cell uptake, and
subsequent release of mitomycin C in the endosome at low pH values.
Reprinted with permission from ref. 34. Copyright © 2014 American
Chemical Society.
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shaped particles, probably due to reduced uptake by the
reticulo-endothelial system.44 The LPNs were used to deliver
anti-Kinesin family member 11 (KIF11) siRNA, as inhibition of
KIF11 is known to prevent centrosome migration and cause
mitotic arrest and apoptosis in various cancers.45 The anti-
cancer eﬃcacy of the nanoparticles was tested in three prostate
cancer cell lines, namely LNCaP, PC3 and DU145; in all cases,
KIF11 knockdown and a reduction in cell viability were
observed.
Yang et al. used a single step nanoprecipitation method to
synthesize LPNs containing cationic lipid BHEM-Chol, the
block polymer mPEG5k-PLA25k and the homopolymer
PLA30k.24 The LPNs showed excellent loading of anti-Plk1
siRNA, good serum stability and cell internalization within
1 h. The nanoparticles were shown to escape from the endo-
lysosome upon internalization, which is essential for post-tran-
scriptional gene silencing in the cytoplasm. Polo-like kinase 1
(Plk1) was chosen for the role it plays in the maturation of the
centrosome, making it a key regulator of cell division in
eukaryotic cells. As the Plk1 oncogene overrides the regulatory
function of p53, inhibition of Plk1 causes apoptosis in cancer
cells by restoring p53 function.46 Anti-Plk1 siRNA nano-
particles inhibited mitotic progression and induced apoptosis
in a BT474 xenograft mouse model, resulting in an almost five-fold
reduction in tumor volume and a more than 60% knockdown
in Plk1 gene expression.
In addition to intracellular drug targets, researchers have
also found extracellular drug targets – the tumor microenviron-
ment and tumor vasculature – to be highly attractive targets.
The following sections describe studies that focus on these
two targets, both of which are critical for tumor growth and
metastasis.
3.3. Targeting the tumor microenvironment
The immediate niche of a tumor is called the tumor micro-
environment. It consists of several types of non-malignant cells,
an extracellular matrix and pre-existing and newly formed
blood vessels, all of which are believed to support and
promote tumor growth and facilitate metastasis.47 Evidence
has shown that cancer cells frequently interact with their
microenvironment, such as by recruiting leukocytes that
secrete pro-proliferation and pro-angiogenic growth
factors.48,49 Hence, aside from targeting the tumor itself,
researchers have increasingly targeted the microenvironment
to achieve a more eﬀective therapeutic response.50
Several features of the tumor microenvironment have been
shown to be relevant for drug delivery using nanocarriers –
namely the slightly elevated temperature, hypoxic and reduc-
tive environments, and leaky tumor vasculature.51 Apart from
exploiting the inherent characteristics of the tumor micro-
environment, various cell types and growth factors associated
with the tumor microenvironment are also being targeted for
eﬀective tumor reduction. For example, tumor-associated
macrophages and stromal cells are possible cellular targets,50
while the vasculature, the lymphatic system, inflammatory pro-
teins and growth factors (such as PDGF, VEGF and HGF) are
also possible molecular targets.50
Photothermal therapy52 and photodynamic therapy53 have
been employed to eﬀectively ablate the tumor microenviron-
ment with some successful studies reported. To ablate the
tumor as well as cells in the surrounding microenvironment,
Zheng et al. developed LPNs containing doxorubicin and indo-
cyanine green (ICG).54 Using a one-step sonication method,
doxorubicin and ICG were loaded into the PLGA core, and
lecithin and DSPE-PEG were self-assembled over the core. ICG
has been approved by the FDA for human use, and can be
used to convert absorbed light into heat for photothermal
applications.55 In addition, its NIR emission around 800 nm
can be used for excellent deep tissue imaging due to low back-
ground autofluorescence. In this study, 8 min of NIR laser
irradiation raised the temperature of the solution from room
temperature to 53.2 degrees, which is suﬃcient to cause irre-
versible damage to the cancer cells. In addition, irradiation led
to thermally-induced disruption of the nanoparticles and doxo-
rubicin release. In both MCF-7 (doxorubicin-sensitive) and
MCF-7/ADR (doxorubicin-resistant) cell lines, the combination
of photothermal therapy and chemotherapy was synergistic
and resulted in significant cell death. Biodistribution studies
performed in an MCF-7 xenograft mouse model showed tumor
accumulation of the nanoparticles. A single nanoparticle dose
combined with laser irradiation led to complete remission for
Fig. 4 Schematic showing the two-step synthesis of lipid/rPAA-Chol
LPNs (above) and LPN intracellular traﬃcking (below). Cellular targeting
is mediated by the T7 peptide. Subsequent siRNA release from the disas-
sembly of the nanoplex leads to silencing of the gene of interest. Repro-
duced with permission from ref. 41. Copyright © 2013, Elsevier Ltd.
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both doxorubicin-sensitive and doxorubicin-resistant tumors,
with no recurrence observed during the 30 day study.
A study by Clawson et al. highlighted a pH-sensitive LPN
system that exploits the acidic nature of the tumor microenviron-
ment.28 The nanoparticles had a pH-sensitive lipid-(succi-
nate)-mPEG shell that is stable at physiological pH but not at
lower pH values. In the acidic tumor microenvironment, the
lipid-(succinate)-mPEG underwent acid hydrolysis, allowing
the PEG layer to be hydrolysed away. Once the PEG shell was
shed, the exposed fusogenic lipids on the nanoparticle surface
facilitated the aggregation of nanoparticles by forming multi-
lamellar lipid structures, as tested in buﬀers with pH values
ranging from 7.4 to 3. Although not shown here, the PLGA
core could be used to encapsulate hydrophobic drugs for
tumor-specific delivery.
In an example of pH-assisted gene delivery, Su et al. used a
double emulsion method to design LPNs. The LPNs had a
reduction-sensitive core of poly(β-amino ester) (PBAE), envel-
oped by a phospholipid bilayer shell consisting of DOPC,
DOTAP and DSPE-PEG.56 The nanoparticles exhibited rapid
dissolution in acidic solutions compared to pH-insensitive
LPNs. Synthetic double-stranded polyriboinosinic-polyribo-
cytidylic acid (poly I/C) mRNA was delivered by loading onto the
LPN surface via electrostatic interaction. Poly I/C was chosen
as it is an eﬀective inducer of interferon and has been shown
to have anti-neoplastic properties in several human cancers.57
Poly I/C loaded LPNs exhibited successful endosomal escape
and antigen presentation in dendritic DC2.4 cells. The
researchers also demonstrated the successful delivery of luci-
ferase-loaded LPNs, which were delivered via intranasal
administration in a C57BL/6J mouse model.
3.4. Targeting the tumor vasculature
Establishing a functional vascular supply is vital for the
growth and development of solid tumors. Tumor-associated
blood vessels are structurally and functionally diﬀerent from
normal vasculature, making the targeting of angiogenesis in
tumors a promising option for cancer therapy.58
Targeting the tumor vasculature presents a new challenge
altogether, since shutting down the tumor vasculature hinders
delivery of therapeutics into the tumor and also increases
hypoxia, which has been correlated with enhanced resistance
and metastasis.59,60 To circumvent these issues, Sengupta
et al. developed a LPN system that used a sequential drug
release strategy: the nanoparticles first released combretastatin
A-4, an anti-angiogenic factor that targets neovasculature, from
the shell, before releasing doxorubicin from the core.22 The
nanoparticles were shown to shut down the vasculature in an
in vitro 3D coculture of endothelial cells, trapping the nano-
particles locally in the tumor microenvironment. The nano-
particles then released doxorubicin in a sustained manner from
the core, ablating melanoma cells in culture. The nanoparticles
were tested in C57/BL6 mice bearing melanoma or Lewis lung
carcinoma tumor xenografts. In survival studies, dual drug
delivery led to superior tumor suppression in comparison with
treatment with either therapeutic delivered alone.
Wang et al. used a sequential drug release strategy similar
to Sengupta et al., but incorporated additional vascular target-
ing factors for active targeting.61 Paclitaxel was loaded into the
PLGA core, while combretastatin A4 was incorporated into a
lipid monolayer containing lecithin, distearoyl-sn-glycero-phos-
phocholine (DSPC), cholesterol and RGDfK peptide-conjugated
DSPE-PEG. Here, RGD targeting peptides were added as they
are known to preferentially bind to the αvβ3 integrin expressed
on tumor endothelial cells. The nanoparticles were tested in
an MCF-7 breast cancer cell line, where they induced signifi-
cant apoptosis; and also in HUVEC cells, where the cells took
up about 90% of the targeted nanoparticles within 1 h in com-
parison with 20% for non-targeted nanoparticles. Temporal
release and sequential eradication of vasculature and the
tumor cells were observed in a 3D co-culture model of endo-
thelial and cancer cells.
Chan et al. designed a hybrid nanoparticle system, called
nanoburrs, to target components of the extracellular matrix.62
The nanoparticles were synthesized by nanoprecipitation and
had a polymeric core (PLA) and a lipid shell (soybean lecithin
and DSPE-PEG). The drug of choice, paclitaxel, was conjugated
to PLA so that it would be released gradually by ester hydro-
lysis. The nanoparticles were surface-functionalized with a
peptide against collagen IV – collagen IV is found in the base-
ment membrane underlying the endothelial monolayer and
plays a major role in angiogenesis, cancer cell growth,
adhesion, migration and diﬀerentiation.63 In vitro, the nano-
burrs showed a sustained release of paclitaxel over 12 days and
reduced the proliferation of human aortic smooth muscle
cells. In ex vivo and in vivo rat injury models, the nanoparticles
were found to accumulate at significantly higher amounts in
angioplastied arteries as compared to healthy arteries. Even
though the nanoburrs were studied in the context of cardio-
vascular disease, they may potentially be used to target the
tumor vasculature.
Despite advancements in the treatment of cancer, two
major hurdles persist – the development of multi-drug resist-
ance and metastasis. Nanomedicine may oﬀer some relief to
traditional chemotherapy approaches, as discussed in the fol-
lowing two sections.
3.5. Targeting multi-drug resistance
Acquiring multi-drug resistance is a major hallmark of many
cancers and poses a big challenge to chemotherapy.64 Selec-
tion pressures from the microenvironment drive the accumu-
lation of mutations in cancer cells, leading to phenotypic
changes such as the overexpression of drug-eﬄuxing protein
pumps.65 Clinically, the presence of multi-drug resistance in
patient tumor biopsies has been correlated to poor pro-
gnosis.66,67 The delivery of drugs using nanoparticles has been
shown to circumvent multi-drug resistance by lowering the
apoptotic threshold of cancer cells.68
Two or more drugs that are used together can cause addi-
tive, synergistic, potentiated or antagonistic eﬀects.69 By deli-
vering multiple agents with favorable interactions, researchers
can target diﬀerent pathways at the same time, discouraging
Review Biomaterials Science
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the development of resistance and achieving better treatment
outcomes compared to single agent therapy.70
In one such example of dual drug delivery, Wong and co-
workers developed LPNs for the co-delivery of a chemothera-
peutic drug (doxorubicin) and a chemosensitizer (Elacridar-
GG918).71 GG918, a new generation of P-glycoprotein (P-gp)
inhibitors with better potency and lower toxicity, works by pre-
venting the eﬄux of doxorubicin from cells. The nanoparticles
were prepared by ultrasonication using a HPESO (hydrolyzed
polymer of epoxidized soybean oil) core and a tristearin–
stearic acid (30 : 70) lipid shell. The nanoparticles were syn-
thesized in the size range of 150–270 nm and had excellent
drug encapsulation eﬃciencies. In a drug resistant cell line,
MDA435/LCC6/MDR1, combination nanoparticles showed two-
fold higher toxicity in comparison with free drug combi-
nations, as GG918 prevented doxorubicin from being eﬄuxed.
Finally, the long-term growth suppressive eﬀect of the LPNs
was tested in a clonogenic assay. The combination drug loaded
nanoparticles showed the lowest IC50 of 0.34 µg mL
−1 and
inhibited colony formation.
Aside from delivering a chemosensitizer to overcome resist-
ance, researchers have also exploited the ability of nanoparticles
to deliver high concentrations of drugs into cancer cells to
overcome resistance. The same group has earlier compared
doxorubicin-loaded LPNs against doxorubicin-conjugated
HPESO polymer nanoparticles.72 The LPNs showed greater
eﬃcacy in vitro compared to HPESO nanoparticles, and were
very eﬀective in overcoming resistance in P-gp over-expressing
MDA435/LCC6 cells and EMT6 cells. The LPNs were observed
to enter the cells via phagocytosis. Concomitantly, the LPNs
released the drugs into the extracellular space, which were
then taken up by the cells by simple diﬀusion.
In an attempt to address multi-drug resistance, Zhang et al.
developed an LPN system for the delivery of mitoxantrone, a
water-soluble cationic drug that is a substrate of P-gp eﬄux
pumps.73 A negatively charged dextran sulfate sodium polymer
was used in the core to maximize drug loading via electrostatic
complexation. The lipid shell was formed using Compritol 888
ATO, Cremophor RH40, Miglyol 812 and lecithin using an
ultrasonication–emulsification method. The nanoparticles
were highly eﬀective in reducing the viability of both drug sen-
sitive MCF-7 cells and drug-resistant, breast cancer resistant
protein (BCRP)-overexpressing MCF-7/MX cells. Mitoxantrone
delivery also increased the sensitivity of resistant cells to drugs
by up to 4.6-fold. Mechanistically, it was demonstrated that
mitoxantrone-loaded nanoparticles entered the cells via cla-
thrin-mediated endocytosis and overcame resistance by escap-
ing BCRP transporter-induced eﬄux.
Another strategy adopted by Prasad et al. to overcome
multi-drug resistance is to co-deliver doxorubicin and mito-
mycin C.15 The nanoparticles contained HPESO in the core, and
contained myristic acid, PEG40SA and PEG100SA in the lipid
monolayer. The nanoparticles showed good in vitro cytotoxicity
in MDA-MB 435/LCC6/WT cells and in P-gp overexpressing
MDA-MB 435/LCC6/MDR1 cells. In an orthotopic human
breast cancer mouse model, treatment with the nanoparticles
led to a 108–151% increase in tumor growth delay, a
210–316% increase in life span, and a 10–20% de facto cure
after treatment. Treated mice did not exhibit any significant
loss in body weight.
3.6. Targeting tumor metastasis
Metastasis presents the single most significant challenge in
cancer management, being the leading cause of treatment fail-
ures.74 About 90% of cancer deaths are due to metastatic
tumors rather than primary tumors. Metastasis encompasses a
complex sequence of events starting with circulating tumor
cells dislodged from a primary tumor. Subsequently, the circu-
lating tumor cells adhere to vascular walls at a secondary site
and migrate across the endothelium to establish a secondary
tumor.75 Recently, researchers have identified an inherently
resistant sub-population of tumor cells, termed cancer stem
cells (CSCs), which play a predominant role in tumor recur-
rence and metastasis.76 Here, we explore studies that use LPNs
to target CSCs or metastatic cancers.
Palange et al. showed that by reducing vascular inflam-
mation, researchers can significantly prevent the metastasis of
primary tumors.23 In this study, they developed NANOCurc
nanoparticles that contain curcumin in the PLGA core and
DPPC and DSPE-PEG in the shell. Curcumin, the active com-
ponent in the turmeric spice, is being increasingly explored as
an anti-cancer agent owing to its anti-inflammatory properties,
one being the inhibition of nitric oxide.77 Curcumin-loaded
LPNs were shown to down-regulate cell adhesion molecules
such as ICAM-1 and MUC-1 within 1 h of treatment. By down-
regulating important cell-surface proteins, vascular inflam-
mation was reduced and the movement of circulating tumor
cells along the vasculature was impaired, thereby preventing
metastasis (Fig. 5). Time- and dose-dependent toxicity was also
observed in MDA-MB231 and HUVEC cells treated with NANO-
Curc nanoparticles.
Conventional immunotherapy has been used to target
metastatic cancers. The over-expression of certain growth
factors (e.g. TGF-β) by the tumor and its microenvironment,
however, impedes the eﬀectiveness of such treatments, as
these growth factors lead to growth deregulation, angiogenesis
and immunosuppressive eﬀects.78 To overcome the inhibitory
eﬀects caused by TGF-β, Park et al. developed liposomal poly-
meric gels loaded with a TGF-β inhibitor (SB505124) and an
immunity-boosting cytokine (IL-2). SB505124 was initially con-
jugated to β-cyclodextrin, after which the nanoparticles were
formed with PC, DSPE-PEG, cholesterol and IL-2 using an
extrusion/freeze drying method. It was observed that encapsu-
lation of the drugs in the nanoparticles decreased drug clear-
ance and improved biodistribution in vivo in a mouse model
of melanoma. The co-loaded nanoparticles showed excellent
inhibitory eﬀects in comparison with nanoparticle-based
monotherapies. The combination treatment also resulted in a
greater than 20% increase (per gram of tumor mass) in acti-
vated CD8+ T lymphocytes compared to untreated mice,
without changing the overall CD4/CD8 ratio and regulatory T
cell numbers. An increase in the number of natural killer cells
Biomaterials Science Review
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per gram of tumor mass was also observed as a result of com-
bination therapy. Thus, apart from tumor reduction, the par-
ticles also activated innate and adaptive immune responses.79
To target the stem cell population in tumors, Gao et al. syn-
thesized LPNs by a single step nanoprecipitation method with
doxorubicin and PLGA in the core and soybean lecithin and
DSPE-PEG-maleimide in the shell.80 In addition, the nano-
particles were surface-conjugated with anti-EGFR antibodies to
target hepatocellular carcinoma cells. The nanoparticles
induced significant toxicity and were taken up by diﬀerent
hepatocellular carcinoma cell lines (SMMC-7721, HepG2 and
Huh7) very eﬃciently. In flow cytometry studies, the percen-
tage of side population cells was found to be reduced by half,
indicating that the LPNs could target CSCs. Finally, in vivo
eﬃcacy studies in an SMMC-7721 HCC xenograft mouse
model showed a five-fold reduction in tumor load in compari-
son with non-targeted nanoparticles and free adriamycin.
Researchers have also developed LPNs for combinatorial
chemotherapy and radiotherapy. Here, Werner et al. delivered
paclitaxel and yttrium-90 (90Y) for the treatment of ovarian
cancer peritoneal metastasis.81 The ChemoRad nanoparticles
had a PLGA core containing paclitaxel and 90Y, and a
shell consisting of DSPE-PEG-folate, lecithin and DMPE-DTPA.
The folate-targeted nanoparticles were taken up more eﬃcien-
tly by folate receptor-overexpressing SKOV3 cells in vitro, as
compared to SW626 cells which do not overexpress the
folate receptor. Clonogenic assays carried out with SKOV3
and OVCAR3 cells showed higher in vitro cytotoxicity by tar-
geted NPs compared to non-targeted NPs. In vivo evaluation of
the targeted ChemoRad NPs in a murine model of ovarian
cancer peritoneal metastasis showed prolonged survival times
and a reduction in tumor growth, while no statistical signifi-
cance could be reached when either therapeutic was used
alone.
Given the versatility of nanoparticulate systems, it is poss-
ible to incorporate additional functionalities such as imaging
into these drug carriers. The ability to track the biodistribution
of LPNs in vivo is highly beneficial in clinical cancer manage-
ment, making highly attractive nanoparticles that can perform
dual roles of drug delivery and imaging. Such LPNs are
described in the following section.
3.7. Theranostic approaches in cancer treatment
According to the American Cancer Society, patient survival
rates for those treated with early stage cancers are much
higher (>90%) than at advanced or metastatic stages, indicat-
ing the importance of diagnosis in cancer treatment. But the
diagnosis of a cancer is not always straightforward, and there
exist many hurdles in using imaging agents in vivo. For
example, there are several intrinsic disadvantages with tra-
ditional fluorophores and contrast agents, and these include
low selectivity and sensitivity, photobleaching, short circula-
tion times and toxicity issues.82
Recent developments in nanotechnology have enabled the
use of nanoparticles for imaging.83 Typically, the fluorescent
dye or contrast agent is encapsulated in the nanoparticles to
overcome their solubility and toxicity issues. Targeting agents
such as antibodies and aptamers can be conjugated onto the
surface of these nanoparticles, while therapeutic agents can be
encapsulated into the core. The ability to combine diagnostics
and therapy, or ‘theranostics’, makes nanoparticles an invalu-
able asset in the clinical toolkit.
In one such example, Aryal et al. developed LPNs for mag-
netic resonance imaging (MRI) using gadolinium ions and
iron oxide nanoparticles.84 The core of the nanoparticle con-
tained PLGA and ultra-small superparamagnetic iron oxide
nanoparticles (USPIO), while the shell contained lipid-PEG
and DOTA chelated to gadolinium ions. The nanoparticles
were uniformly sized, monodisperse and showed good contrast
agent loading. They also had significantly higher magnetic
relaxivities in comparison with commercially available contrast
agents, and showed eﬃcient uptake by J-774 cells in vitro. In a
murine B16-F10 xenograft model, the nanoparticles accumu-
lated in the tumor within 3 h and showed excellent contrast.
Here, drug loading was not demonstrated although the PLGA
core could be used to encapsulate drugs.
Aside from MRI imaging, researchers have also used gold
nanoparticles for computed tomography (CT) imaging. In a
Fig. 5 Schematic representation of the metastatic process and mech-
anism of action for NANOCurc. (A) Circulating tumor cells metastasize
from the primary site and form tumors at a secondary site. The inset
shows the interaction of a tumor cell with endothelial cells through
adhesion molecules. (B) NANOCurc treatment inhibits metastasis by
reducing the expression of adhesion molecules on endothelial cells.
Reproduced with permission from ref. 23. Copyright © 2014, Elsevier
Inc.
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study by Willem et al., gold nanoparticles and quantum dots
were chemically conjugated to the PLGA core and coated with
soybean lecithin and DSPE-PEG.14 The gold nanoparticles were
useful for CT imaging and the quantum dots were useful for
fluorescence imaging, as tested in J-774A.1 mouse macrophage
cells in vitro. Once again, the PLGA core could be used to
encapsulate therapeutic molecules but the researchers did not
demonstrate so in their study.
Liao et al. developed LPNs for simultaneous imaging and
drug delivery.85 Doxorubicin was loaded into the PLGA core,
after which it was coated with a paramagnetic lipid shell con-
sisting of amphiphilic octadecyl-quaternized lysine-modified
chitosan (OQLCS) individually conjugated to PEG, Gd-DTPA
and folic acid by gentle hydration. Here, the nanoparticles
were modified with folic acid for cancer-specific targeting and
gadolinium for contrast enhancement. In in vitro studies, the
nanoparticles showed good stability and better contrast than
commercially available contrast agents such as Magnevist®.
The nanoparticles also loaded doxorubicin eﬃciently and were
taken up by HeLa cells within 4 h. The cytotoxic eﬀect of the
drug-loaded nanoparticles was slightly lower than with free
doxorubicin but was comparable.
In another example of theranostic application of LPNs,
Mieszawska et al. used a microfluidic technique to synthesize
LPNs. The LPNs consisted of PLGA, gold nanoparticles (for CT
imaging) and doxorubicin (hydrophobic drug) in the core fol-
lowed by sorafenib (lipophilic drug) and Cy7 (for near infrared
imaging) in the shell.86 The nanoparticles exhibited controlled
drug release over 20 days, and inhibited growth in LS174 T
cancer cell lines. The biodistribution of the nanoparticles was
studied in a LS174 T xenograft mouse model. Both 3D CT
imaging and near infrared fluorescence imaging showed nano-
particle accumulation to be significant only in the tumor 18 h
post injection.
4. Conclusions and future directions
The last decade has seen interesting developments in the field
of lipid–polymer hybrid nanotechnology. There has been an
exponential increase in the number of studies performed
using these hybrid systems, with a dazzling array of surface
coatings and encapsulated cargoes. Not only have these LPNs
been used to deliver therapeutic molecules such as small
molecules, plasmids, siRNA, proteins and peptides, they have
also been used to deliver diagnostic molecules such as iron
oxide nanoparticles, fluorescent dyes, quantum dots and gold
nanoparticles. These systems have been tested in both in vitro
and in vivo models.
Although LPNs encompass the advantages of both poly-
meric nanoparticles and liposomes, they present new chal-
lenges that may impede clinical translation. For example, a
multi-step synthesis process is required due to the use of two
classes of biomaterials (lipids and polymers), which may make
scale-up manufacturing more challenging. There are also
additional economic and quality considerations when produ-
cing the LPNs on a large scale. Researchers need to define all
of the component ingredients at a molecular level, and evalu-
ate their safety and biocompatibility in vivo. Thus, the develop-
ment of simple and scalable protocols for the synthesis of
LPNs, using FDA-approved materials with highly predictable
in vivo characteristics, will enable faster clinical translation.
Although LPNs present a number of advantages in that they
can deliver both hydrophobic and hydrophilic cargo and also
be functionalized for active targeting, more studies need to be
done at the pre-clinical stage. For example, the majority of
cancer therapeutic studies reported in the literature using
LPNs have only been tested in in vitro models. More investiga-
tional new drug (IND) type studies focusing on in vivo anti-
tumor eﬃcacy, biodistribution, clearance and long-term toxicity
will need to be performed.
Apart from IND studies, there are also several interesting
novel techniques that could be explored further. One such
example is the recent development of ‘cell ghosts’, which are
LPN-like nanoparticles that use biologically derived lipid mem-
branes isolated from cells in place of synthetic lipids.87 Such
nanoparticles may have unique biological functionalities
depending upon the cell type chosen and hold immense
potential for cancer treatment. For example, coating a nano-
particle with biological cell membranes bearing self-antigens
will prolong their circulation half-life; these particles may
more eﬀectively evade the reticulo-endothelial system com-
pared to synthetic stealth materials such as PEG. Further,
coating nanoparticles with biological membranes already
having the right display of cell-surface ligands can lead to
more precise targeting, compared with transfection and
expression of the cell-surface ligand using genetic modifi-
cation techniques. While cell ghost technology is very
appealing given its potential, several factors like cross-immu-
nogenicity, uniformity and feasibility of large scale synthesis
need to be investigated in detail.
With more pre-clinical studies (and possibly clinical
studies) foreseen to take place over the next few years, we
believe that more encouraging data will be reported that
demonstrate the versatility of LPNs as a drug delivery carrier
and a platform of choice for cancer drug delivery.
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